Chronic pain due to osteoarthritis (OA) can lead to significant disruption of sleep and increased restlessness. Our objective was to assess whether naturally occurring canine OA is associated with nighttime restlessness and so has potential as a model of OA-associated sleep disturbance. The study was designed as a two-part prospective masked, placebo-controlled study using client-owned dogs (Part A n = 60; Part B n = 19). Inclusion criteria consisted of OA-associated joint pain and mobility impairment. The primary outcome measure for both parts was nighttime accelerometry. In Part B, quality of sleep was assessed using a clinical metrology instrument (Sleep and Night Time Restlessness Evaluation Score, SNoRE). Part A included dogs receiving two weeks of non-steroidal anti-inflammatory drug (NSAID) preceded with two weeks of no treatment. Part B was a crossover study, with NSAID/placebo administered for two weeks followed by a washout period of one week and another two weeks of NSAID/placebo. Repeated measures analysis of variance was used to assess differences between baseline and treatment. There were no significant changes in accelerometry-measured nighttime activity as a result of NSAID administration. SNoRE measures indicated significant improvements in aspects of the quality of nighttime sleep that did not involve obvious movement. These results reflect the few similar studies in human OA patients. Although accelerometry does not appear to be useful, this model has potential to model the human pain-related nighttime sleep disturbance, and other outcome measures should be explored in this model.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340376 | PMC |
http://dx.doi.org/10.7717/peerj.772 | DOI Listing |
Cureus
November 2024
Pediatrics, Child and Parents Support Clinic, Ebina, JPN.
Melatonin is commonly used to treat sleep disorders. Regardless of the prolactin level elevation induced by melatonin administration, breast budding is not known to develop as a result of this treatment. A 10-year-old boy presented to our outpatient clinic with restlessness and sleep disorders.
View Article and Find Full Text PDFExpert Opin Pharmacother
November 2024
Faculty of Medicine, Transilvania University of Braşov, Brașov, Romania.
Neurol Res
December 2024
Neurology Clinic, Sakarya University Faculty of Medicine, Sakarya, Türkiye.
Study Objectives: Disrupted nighttime sleep (DNS) and sleep instability are common in children and adolescents with Narcolepsy Type 1 (NT1), but optimal objective sleep measures have not been determined. We compared self-reported and objective sleep measures between young people with NT1 and healthy controls (HC) and test the hypotheses that the Wake/N1 Index is the best objective measure of perceived nocturnal wakings vs. other DNS measures reported in the literature and is associated with daytime functional problems.
View Article and Find Full Text PDFPharmacol Rep
December 2024
Department of Algorithms and System Modeling, Gdansk University of Technology, Gdańsk, Poland.
Background: This study examines self-reported sleep alterations in treatment-resistant depression (TRD) inpatients following intravenous ketamine administration.
Methods: This is a post-hoc analysis of a naturalistic observational study, which enrolled 28 inpatients with treatment-resistant major depressive disorder and analyzed self-reported sleep changes (items 1-4; 'insomnia', 'nighttime restlessness', 'early morning waking', 'hypersomnia') in Inventory of Depressive Symptomatology 30-item (IDS SR-30) in responders and non-responders stratified per Montgomery-Åsberg Depression Rating Scale (MADRS) during short-term ketamine treatment.
Results: Responders, as well as non-responders, did not experience significant changes in IDS SR-30 sleep items ('insomnia', 'nighttime restlessness', 'early morning waking', 'hypersomnia') (p's > 0.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!